← Back to Analyst Consensus 
TLSI Buy
TriSalus Life Sciences, Inc.
Current Price —
Implied Upside —
Analysts 11
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 10, 2026 (15 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 23, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Sep 9, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| May 13, 2026 | Lake Street | maintain | Buy → Buy | — | 47% |
| Mar 9, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Mar 6, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Dec 17, 2025 | Canaccord Genuity | maintain | Buy → Buy | $12 | 48% |
| Mar 28, 2025 | Canaccord Genuity | maintain | Buy → Buy | $11 | 48% |
| Feb 13, 2025 | Lake Street | initiate | — → Buy | $10 | 47% |
| Jan 24, 2025 | Roth MKM | reiterate | Buy → Buy | $11 | 52% |
| Dec 17, 2024 | Cantor Fitzgerald | initiate | — → Overweight | $10 | 50% |
| Nov 15, 2024 | Canaccord Genuity | maintain | Buy → Buy | $11 | 48% |
| Nov 11, 2024 | Roth MKM | initiate | — → Buy | $11 | 52% |
| Oct 25, 2024 | Northland Capital Markets | initiate | — → Outperform | $12.5 | 50% |
| Sep 16, 2024 | Oppenheimer | initiate | — → Outperform | $10 | 52% |
| Jun 27, 2024 | Canaccord Genuity | maintain | Buy → Buy | $12 | 48% |
| May 30, 2024 | Canaccord Genuity | initiate | — → Buy | $12 | 48% |
| May 10, 2024 | JonesTrading | initiate | — → Buy | $16 | 75% |
Price Target Trend
Apr 1, 2026 Latest: $10.4 Oct 24, 2026
EPS Estimates
0q $-0.13
Lo: $-0.15 Hi: $-0.09
5 analysts 0y $-0.33
Lo: $-0.39 Hi: $-0.27
5 analysts +1q $-0.06
Lo: $-0.11 Hi: $-0.04
5 analysts ▲1
+1y $-0.26
Lo: $-0.38 Hi: $0.02
5 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days